Effects of Spermidine Supplementation on Cognition and Biomarkers in Older Adults With Subjective Cognitive Decline: A Randomized Clinical Trial
Schwarz C, Benson GS, Horn N, Wurdack K
Published in JAMA Network Open
Methodology
12-month randomized, double-masked, placebo-controlled phase 2b trial of wheat-germ spermidine 0.9 mg/day versus microcrystalline cellulose placebo
Key Findings
No significant change in memory performance or biomarkers over 12 months; exploratory analyses hinted at effects on inflammation and verbal memory.
Conclusions
Longer-term spermidine supplementation did not modify memory or biomarkers versus placebo.
Limitations
Low spermidine dose may have been insufficient, single centre, at-risk but non-demented population, exploratory findings unconfirmed.
Supplements Studied
Longer-term spermidine supplementation did not improve memory in older adults with subjective cognitive decline.
Outcomes Measured
Longer-term spermidine supplementation did not improve memory in older adults with subjective cognitive decline.
Over 12 months, no significant changes were observed in mnemonic discrimination performance (between-group difference, -0.03; 95% CI, -0.11 to 0.05; P = .47) and secondary outcomes.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Academic/non-industry research support
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.